Cargando…

Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia

BACKGROUND: The effectiveness of glucose-lowering drugs (GLDs) is unknown among patients with dementia. OBJECTIVE: To analyze all-cause mortality among users of six GLDs in dementia and dementia-free subjects, respectively. METHODS: This was a longitudinal open-cohort registry-based study using data...

Descripción completa

Detalles Bibliográficos
Autores principales: Secnik, Juraj, Xu, Hong, Schwertner, Emilia, Hammar, Niklas, Alvarsson, Michael, Winblad, Bengt, Eriksdotter, Maria, Garcia-Ptacek, Sara, Religa, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028644/
https://www.ncbi.nlm.nih.gov/pubmed/35034902
http://dx.doi.org/10.3233/JAD-215337
_version_ 1784691672786927616
author Secnik, Juraj
Xu, Hong
Schwertner, Emilia
Hammar, Niklas
Alvarsson, Michael
Winblad, Bengt
Eriksdotter, Maria
Garcia-Ptacek, Sara
Religa, Dorota
author_facet Secnik, Juraj
Xu, Hong
Schwertner, Emilia
Hammar, Niklas
Alvarsson, Michael
Winblad, Bengt
Eriksdotter, Maria
Garcia-Ptacek, Sara
Religa, Dorota
author_sort Secnik, Juraj
collection PubMed
description BACKGROUND: The effectiveness of glucose-lowering drugs (GLDs) is unknown among patients with dementia. OBJECTIVE: To analyze all-cause mortality among users of six GLDs in dementia and dementia-free subjects, respectively. METHODS: This was a longitudinal open-cohort registry-based study using data from the Swedish Dementia Registry, Total Population Register, and four supplemental registers providing data on dementia status, drug usage, confounders, and mortality. The cohort comprised 132,402 subjects with diabetes at baseline, of which 11,401 (8.6%) had dementia and 121,001 (91.4%) were dementia-free. Subsequently, comparable dementia – dementia-free pairs were sampled. Then, as-treated and intention-to-treat exposures to metformin, insulin, sulfonylurea, dipeptidyl-peptidase-4 inhibitors, glucagon-like peptide-1 analogues (GLP-1a), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were analyzed in the parallel dementia and dementia-free cohorts. Confounding was addressed using inverse-probability weighting and propensity-score matching, and flexible parametric survival models were used to produce hazard ratios (HR) and 95% confidence intervals (CI) of the association between GLDs and all-cause mortality. RESULTS: In the as-treated models, increased mortality was observed among insulin users with dementia (HR 1.34 [95%CI 1.24–1.45]) as well as in dementia-free subjects (1.54 [1.10–1.55]). Conversely, sulfonylurea was associated with higher mortality only in dementia subjects (1.19 [1.01–1.42]). GLP-1a (0.44 [0.25–0.78]) and SGLT-2i users with dementia (0.43 [0.23–0.80]) experienced lower mortality compared to non-users. CONCLUSION: Insulin and sulfonylurea carried higher mortality risk among dementia patients, while GLP-1a and SGLT-2i were associated with lower risk. GLD-associated mortality varied between dementia and comparable dementia-free subjects. Further studies are needed to optimize GLD use in dementia patients.
format Online
Article
Text
id pubmed-9028644
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-90286442022-05-06 Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia Secnik, Juraj Xu, Hong Schwertner, Emilia Hammar, Niklas Alvarsson, Michael Winblad, Bengt Eriksdotter, Maria Garcia-Ptacek, Sara Religa, Dorota J Alzheimers Dis Research Article BACKGROUND: The effectiveness of glucose-lowering drugs (GLDs) is unknown among patients with dementia. OBJECTIVE: To analyze all-cause mortality among users of six GLDs in dementia and dementia-free subjects, respectively. METHODS: This was a longitudinal open-cohort registry-based study using data from the Swedish Dementia Registry, Total Population Register, and four supplemental registers providing data on dementia status, drug usage, confounders, and mortality. The cohort comprised 132,402 subjects with diabetes at baseline, of which 11,401 (8.6%) had dementia and 121,001 (91.4%) were dementia-free. Subsequently, comparable dementia – dementia-free pairs were sampled. Then, as-treated and intention-to-treat exposures to metformin, insulin, sulfonylurea, dipeptidyl-peptidase-4 inhibitors, glucagon-like peptide-1 analogues (GLP-1a), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were analyzed in the parallel dementia and dementia-free cohorts. Confounding was addressed using inverse-probability weighting and propensity-score matching, and flexible parametric survival models were used to produce hazard ratios (HR) and 95% confidence intervals (CI) of the association between GLDs and all-cause mortality. RESULTS: In the as-treated models, increased mortality was observed among insulin users with dementia (HR 1.34 [95%CI 1.24–1.45]) as well as in dementia-free subjects (1.54 [1.10–1.55]). Conversely, sulfonylurea was associated with higher mortality only in dementia subjects (1.19 [1.01–1.42]). GLP-1a (0.44 [0.25–0.78]) and SGLT-2i users with dementia (0.43 [0.23–0.80]) experienced lower mortality compared to non-users. CONCLUSION: Insulin and sulfonylurea carried higher mortality risk among dementia patients, while GLP-1a and SGLT-2i were associated with lower risk. GLD-associated mortality varied between dementia and comparable dementia-free subjects. Further studies are needed to optimize GLD use in dementia patients. IOS Press 2022-03-08 /pmc/articles/PMC9028644/ /pubmed/35034902 http://dx.doi.org/10.3233/JAD-215337 Text en © 2022 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Secnik, Juraj
Xu, Hong
Schwertner, Emilia
Hammar, Niklas
Alvarsson, Michael
Winblad, Bengt
Eriksdotter, Maria
Garcia-Ptacek, Sara
Religa, Dorota
Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
title Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
title_full Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
title_fullStr Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
title_full_unstemmed Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
title_short Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
title_sort glucose-lowering medications and post-dementia survival in patients with diabetes and dementia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028644/
https://www.ncbi.nlm.nih.gov/pubmed/35034902
http://dx.doi.org/10.3233/JAD-215337
work_keys_str_mv AT secnikjuraj glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia
AT xuhong glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia
AT schwertneremilia glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia
AT hammarniklas glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia
AT alvarssonmichael glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia
AT winbladbengt glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia
AT eriksdottermaria glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia
AT garciaptaceksara glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia
AT religadorota glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia